Cargando…
Levetiracetam alleviates cognitive decline in Alzheimer’s disease animal model by ameliorating the dysfunction of the neuronal network
BACKGROUND: Patients with Alzheimer’s disease (AD) have a significantly higher risk of seizures than other individuals in an age-matched population, suggesting a close association between epilepsy and AD. We aimed to examine the effects of levetiracetam (LEV)—a drug for treating seizures—on learning...
Autores principales: | Zheng, Xiang-Yu, Zhang, Hai-Chen, Lv, Yu-Dan, Jin, Feng-Yan, Wu, Xiu-Juan, Zhu, Jie, Ruan, Yang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9452890/ https://www.ncbi.nlm.nih.gov/pubmed/36092803 http://dx.doi.org/10.3389/fnagi.2022.888784 |
Ejemplares similares
-
Cognitive dysfunction in Nigerian women with epilepsy on carbamazepine and levetiracetam monotherapy
por: Ogunjimi, Luqman, et al.
Publicado: (2021) -
An intranasally delivered peptide drug ameliorates cognitive decline in Alzheimer transgenic mice
por: Cheng, Yu‐Sung, et al.
Publicado: (2017) -
Staged decline of neuronal function in vivo in an animal model of Alzheimer's disease
por: Grienberger, Christine, et al.
Publicado: (2012) -
Levetiracetam treatment ameliorates LRRK2 pathological mutant phenotype
por: Rassu, Mauro, et al.
Publicado: (2019) -
Neuronal-Derived EV Biomarkers Track Cognitive Decline in Alzheimer’s Disease
por: Eren, Erden, et al.
Publicado: (2022)